Chest
CorrespondenceAnticoagulant Therapy and Idiopathic Pulmonary Fibrosis
Section snippets
To the Editor
We read with interest the report by Kubo and colleagues1 of a randomized controlled trial of anticoagulation and corticosteroids vs corticosteroids alone in 56 Japanese patients with idiopathic pulmonary fibrosis (IPF). The authors should be commended for applying sound biological rationale in developing a promising hypothesis, and the results provide hope that anticoagulation may benefit patients with IPF. However, there are three substantial methodologic issues in this study, and physicians
References (4)
- et al.
Anticoagulant therapy for idiopathic pulmonary fibrosis
Chest
(2005) - et al.
The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study
Chest
(1999)
Cited by (20)
Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells
2020, European Journal of PharmacologyCitation Excerpt :It should be noted that anticoagulation with inhibitors of FXa or thrombin was able to limit bleomycin-induced pulmonary fibrosis in mice (Scotton et al., 2009; Howell et al., 2001). The recent observations induced growing interest in evaluation of inhibitors of thrombin or FXa in diseases associated with chronic inflammatory injury (Borensztajn et al., 2011; Kubo et al., 2005; Bogatkevich et al., 2009; Kinder et al., 2006; Shi et al., 2018). To date, it is not known whether FXa has cellular effects in airway epithelial cells.
Pulmonary hypertension in idiopathic pulmonary fibrosis
2007, ChestCitation Excerpt :Long-term anticoagulation has been associated with better outcomes in a nonrandomized epidemiologic study15 of PAH. One RCT6162 in IPF suggested better outcomes with anticoagulation, although the lack of a placebo-control arm and masking limit the conclusions that can be drawn from this study. In summary, there are several potential therapies for PH in IPF; however, convincing data regarding efficacy do not exist.
Pulmonary hypertension in idiopathic interstitial pneumonias
2017, Pulmonary Hypertension and Interstitial Lung DiseaseTargeting coagulation factor receptors – protease-activated receptors in idiopathic pulmonary fibrosis
2017, Journal of Thrombosis and HaemostasisIPF: Treatment and prevention of pulmonary exacerbations
2017, ERS Monograph
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
The authors have no conflicts of interest to disclose.